

ANIKA THERAPEUTICS INC
Form 8-K
June 12, 2012

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2012

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts	000-21326	04-3145961
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification
32 Wiggins Avenue		No.)

Bedford, Massachusetts	01730
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(781) 457-9000**

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders on June 7, 2012. Proxies were solicited pursuant to the Company’s proxy statement filed on April 25, 2012, with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. There was no solicitation in opposition to the Company’s solicitation. At the Annual Meeting, holders of the Company’s common stock were asked:

1. To elect two (2) Class I directors nominated by the Board of Directors, each to serve until the 2015 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified;
2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2012 fiscal year; and
3. To consider and approve an advisory vote regarding the compensation of the Company’s Named Executive Officers.

A total of 12,110,903 shares of the Company’s common stock were present in person or by proxy at the Annual Meeting, representing approximately 88% of the voting power of the Company entitled to vote at the Annual Meeting. Each share of the Company’s common stock was entitled to one vote with respect to matters submitted to a vote of the Company’s stockholders, and the voting results reported below are final.

PROPOSAL 1

Each of the Company’s nominees for director as listed in the proxy statement was re-elected as shown in the table below:

Nominee	Votes		Broker
	Votes “For”	Withheld	Non-Votes
Joseph L. Bower	7,258,978	261,839	4,590,086
Jeffery S. Thompson	7,258,751	262,066	4,590,086

PROPOSAL 2

Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2012 fiscal year as shown in the table below:

For	Broker		
	Against	Abstained	Non-Votes
11,587,877	517,893	5,133	0

PROPOSAL 3

Stockholders approved, on an advisory basis, the compensation paid to the Company's Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion set forth in the Proxy Statement for the Annual Meeting as shown in the table below:

Broker

For	Against	Abstained	Non-Votes
7,319,354	155,925	45,538	4,590,086

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anika Therapeutics, Inc.

Date: June 11, 2012 By: /s/ Kevin W. Quinlan
Name: Kevin W. Quinlan
Title: Chief Financial Officer